Incyte (NASDAQ:INCY) Sets New 12-Month High – Here’s Why

Incyte Corporation (NASDAQ:INCY) shares hit a new 52-week high on Monday . The company traded as high as $120.19 and last traded at $120.09, with a volume of 276626 shares trading hands. The stock had previously closed at $117.67.

Incyte News Roundup

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Quarterly results exceeded expectations. Incyte reported $1.67 billion in second-quarter revenue, up 37.7% year over year and above the $1.50 billion consensus estimate. Adjusted EPS of $3.09 also surpassed the $2.20 consensus, while GAAP net income reached $585.6 million. Incyte earnings results
• Positive Sentiment: Management raised full-year 2026 guidance. Total net sales guidance increased to $5.13 billion-$5.26 billion from $4.77 billion-$4.94 billion. The improved outlook reflects stronger expectations for Opzelura and the Hematology and Oncology portfolio. INCY Q2 earnings and guidance
• Positive Sentiment: Product growth broadened beyond Jakafi. Jakafi and Jakafi XR sales rose 7% to $817 million, while Opzelura sales surged 173% to $450 million and Hematology and Oncology sales increased 69% to $222 million. Management said growth from Jakafi, Opzelura, Niktimvo, Monjuvi and Zynyz supports a more diversified commercial business. Incyte is no longer a one-drug story
• Positive Sentiment: A CMS-related Opzelura agreement boosted the outlook. Incyte expects the agreement to contribute approximately $300 million-$310 million to 2026 Opzelura sales, including a $246 million one-time, non-cash benefit recognized in the quarter. The company also expects 10 clinical readouts, including four registrational trials, during the second half of 2026. Incyte raises sales outlook
• Neutral Sentiment: Incyte discontinued an early-stage JAK inhibitor program to focus resources on next-generation pipeline candidates. This may improve strategic focus but removes one development opportunity. Incyte JAK inhibitor decision
• Negative Sentiment: Some risks remain after the rally. A Seeking Alpha contributor downgraded the stock from Buy to Hold following its substantial advance, and the median analyst price target of $105 is below recent trading levels. In addition, reported insider activity showed sales but no purchases over the past six months. Incyte rating downgrade

Analyst Upgrades and Downgrades

INCY has been the topic of a number of research analyst reports. Morgan Stanley increased their price target on shares of Incyte from $103.00 to $104.00 and gave the stock an “equal weight” rating in a report on Thursday, July 23rd. Oppenheimer reaffirmed a “market perform” rating and set a $120.00 price objective on shares of Incyte in a report on Tuesday. Barclays upped their target price on shares of Incyte from $117.00 to $134.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 14th. JPMorgan Chase & Co. increased their target price on Incyte from $105.00 to $110.00 and gave the company a “neutral” rating in a research note on Thursday, July 23rd. Finally, Citigroup restated a “market perform” rating on shares of Incyte in a research report on Wednesday, July 15th. Eight investment analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $112.85.

Incyte Price Performance

The business has a 50-day simple moving average of $107.99 and a 200 day simple moving average of $101.86. The firm has a market cap of $25.96 billion, a P/E ratio of 18.35, a price-to-earnings-growth ratio of 1.03 and a beta of 0.76. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.60 and a current ratio of 3.68.

Incyte (NASDAQ:INCY) last issued its quarterly earnings data on Tuesday, July 28th. The biopharmaceutical company reported $3.09 earnings per share for the quarter, topping analysts’ consensus estimates of $2.20 by $0.89. Incyte had a return on equity of 26.66% and a net margin of 26.71%.The firm had revenue of $1.67 billion for the quarter, compared to analyst estimates of $1.50 billion. During the same period last year, the company earned $1.57 EPS. The business’s quarterly revenue was up 37.7% compared to the same quarter last year. On average, analysts anticipate that Incyte Corporation will post 6.9 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Elyxium Wealth LLC purchased a new stake in shares of Incyte in the 4th quarter worth about $28,000. Smithfield Trust Co increased its position in shares of Incyte by 135.0% during the fourth quarter. Smithfield Trust Co now owns 282 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 162 shares during the period. University of Texas Texas AM Investment Management Co. purchased a new position in shares of Incyte during the fourth quarter valued at about $35,000. Atlas Capital Advisors Inc. bought a new position in Incyte in the fourth quarter worth about $35,000. Finally, Leonteq Securities AG purchased a new stake in Incyte in the fourth quarter worth about $35,000. 96.97% of the stock is owned by hedge funds and other institutional investors.

About Incyte

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.